


PRO-C3 measures active fibrogenesis with FDA support for enrichment and stratification

PRO-C3 quantifies type III collagen formation from active fibroblasts. It meets three key criteria: diagnostic (identifies patients with active fibrosis), prognostic (predicts outcomes), and pharmacodynamic (measures treatment efficacy). FDA supports PRO-C3 for clinical trial enrichment and stratification.

PRO-C3: A unicorn biomarker?

PRO-C3 measures active fibrosis

PRO-C3 measures active fibrosis



FDA supports the use of PRO-C3

The 3 criteria's:

- **Diagnosis:** PRO-C3 can diagnose patients with active fibrosis
- **Prognosis:** PRO-C3 is prognostic for liver outcomes
- **Pharmacodynamic:** PRO-C3 can measure efficacy of anti-fibrotic therapies

FDA supports PRO-C3 for clinical trial enrichment and stratification.

